Comparative Pharmacology
Head-to-head clinical analysis: DIULO versus HYDROCHLOROTHIAZIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIULO versus HYDROCHLOROTHIAZIDE INTENSOL.
DIULO vs HYDROCHLOROTHIAZIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na+/Cl- symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased diuresis and decreased extracellular fluid volume.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
2.5 mg orally once daily, may increase to 5 mg once daily after 4 weeks if needed.
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours (mean 1.8 h) in healthy adults; prolonged to 3-6 hours in renal impairment and up to 8 hours in severe heart failure.
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
Primarily renal excretion (60-70% as unchanged drug) via glomerular filtration and tubular secretion; approximately 10-15% biliary/fecal elimination.
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic